Compare Matson Inc (MATX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Sanofi SA — how do they compare? Matson Inc trades at $224.92 (market cap $6.81B), while Sanofi SA trades at $40.15 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 14× Matson Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and Sanofi SA for 94 Days on average.
| MATX | SNY | |
|---|---|---|
Market Cap | $6.81B | $95.18B |
Volume | 255,080 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $238.60 | $52.34 |
52-Week Low | $88.05 | $39.51 |
Typical Hold Time | 23 Days | 94 Days |
Enterprise Value | $7.41B | $114.48B |
Dividend Yield | 0.67% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $224.80, up 0.84% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong Q2 2026 earnings of $4.27 per share, beating estimates, and raised its full-year outlook. Revenue growth is steady, with 2026 revenue projected at $3.5 billion and net profit at $464 million, supported by a robust net income margin of 13.41%.
The outlook for MATX is positive, driven by earnings beats, cost controls, and institutional accumulation. Key risks include exposure to freight demand cycles and competitive pressures. Wall Street consensus is bullish, with 8 of 12 analysts rating it a Buy and an implied 27.33% upside potential, though investors should monitor macroeconomic trends affecting transportation stocks.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
